Abstract: There is provided a peracetic acid concentration meter that inhibits contamination of a working electrode surface by organic material, and makes it possible to measure a peracetic acid concentration more accurately than is possible conventionally. The present invention is a diaphragm-type peracetic acid concentration meter that measures a peracetic acid concentration in a test solution and is characterized in being provided with a diaphragm that is permeable to peracetic acid, an internal solution in which peracetic acid that has permeated through the diaphragm is dissolved, a working electrode and a counter electrode that are immersed in the internal solution, and a permeation-inhibiting layer that is laminated onto a surface of the diaphragm on a side thereof that is in contact with the test solution, and that inhibits permeation of organic material.

Abstract: A main object of the present invention is to provide a membrane covered type peracetic acid concentration meter that can prevent various common problems, including problems that occur in the event of an internal solution leak into a sample solution. The membrane covered type peracetic acid concentration meter adapted to measure the concentration of peracetic acid in the sample solution includes: a membrane that allows peracetic acid to permeate; and the internal solution that dissolves peracetic acid having permeated the membrane. In addition, as the internal solution, a buffer solution having a buffering action on hydrogen ion concentration is used.

Abstract: An endoscope reprocessor includes a concentration sensor including a concave section in which a sensing section is housed and a permeable membrane configured to cover the concave section, a medicinal solution tank, to an inside of which at least the permeable membrane is exposed and on the inside of which a disinfection solution is stored, and a heating section configured to heat at least the permeable membrane.

Abstract: An endoscope reprocessor includes a concentration sensor including a concave section in which a sensing section is housed and a permeable membrane configured to cover the concave section, a pressure resistant container in which the concentration sensor is housed, a medicinal-solution lead-in section configured to introduce a medicinal solution into the pressure resistant container, and a pressure adjusting section configured to adjust pressure such that an internal pressure of the concave section is low compared with an internal pressure of the pressure resistant container.

Abstract: An endoscope reprocessor includes a concentration sensor including a concave section in which a sensing section is housed and a permeable membrane configured to cover the concave section, a pressure resistant container in which the concentration sensor is housed, a medicinal-solution lead-in section configured to introduce a medicinal solution into the pressure resistant container, and a pressure adjusting section configured to adjust pressure such that an internal pressure of the concave section is low compared with an internal pressure of the pressure resistant container.

Abstract: An endoscope reprocessor includes a concentration sensor including a concave section in which a sensing section is housed and a permeable membrane configured to cover the concave section, a medicinal solution tank, to an inside of which at least the permeable membrane is exposed and on the inside of which a disinfection solution is stored, and a heating section configured to heat at least the permeable membrane.

Abstract: A main object of the present invention is to provide a membrane covered type peracetic acid concentration meter that can prevent various common problems, including problems that occur in the event of an internal solution leak into a sample solution. The membrane covered type peracetic acid concentration meter adapted to measure the concentration of peracetic acid in the sample solution includes: a membrane that allows peracetic acid to permeate; and the internal solution that dissolves peracetic acid having permeated the membrane. In addition, as the internal solution, a buffer solution having a buffering action on hydrogen ion concentration is used.

Abstract: A novel receptor, “LDL-receptor-related protein-5” (“LRP-5”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.

Abstract: A novel receptor, “LDL-receptor-related protein-3” (“LRP-3”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.

Abstract: A novel receptor, “LDL-receptor related protein-3” (“LRP-3”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.

Abstract: A novel receptor, “LDL-receptor related protein-3” (“LRP-3”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.

Abstract: Rice-bran wax in the amount of 0.1 to 10 parts by weight per 100 parts of elastomer is added to fluoroelastomers to improve the processability of the fluoroelastomer.